Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Triple Negative Breast Neoplasms 1Sarcoma 1Pathologic Complete Response 1Neoplasms 1Lymphoma 1Hemangiosarcoma 1Carcinoma 1Breast Neoplasms 1

Interventions

Cisplatin 21pembrolizumab 16Gemcitabine 16Paclitaxel 15Radiotherapy 14Carboplatin 14Radiotherapy, Intensity-Modulated 13Cyclophosphamide 9Cetuximab 9Magnetic Resonance Spectroscopy 8Radiation 7padeliporfin 6Specimen Handling 6Oxaliplatin 6Fluorouracil 6Drug Therapy 6Docetaxel 6Capecitabine 6Bevacizumab 6anlotinib 5Nivolumab 5Irinotecan 5Erlotinib Hydrochloride 5Celecoxib 5poly ICLC 4fludarabine 4Standard of Care 4Sorafenib 4Leucovorin 4Ipilimumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma × patritumab × Clear all
NCT01479023 2013-12-20

Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors

Washington University School of Medicine

Phase 1 Terminated
12 enrolled
LymphoidSarcoma

Carcinoma, Lymphoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡